This is our single-player campaign review for Call of Duty: Modern Warfare 2. For our thoughts on PvP, check out the multiplayer review. In five years time when we discuss Call of Duty: Modern Warfare ...

If iCloud is not syncing your files and folders from an iPhone, iPad, iPod touch, or Mac to a Windows PC, this post will help you fix the issue. Many users have reported experiencing sync issues while ...

Share on Pinterest Experimental drug could reduce harmful liver and visceral fat, without significant muscle loss. Image credit: MNT Design/Photo by Mariia Vitkovska/Schankz/Getty Images In the phase ...

Boehringer Ingelheim disclosed full Phase 3 data for survodutide at the American Diabetes Association's 2026 Scientific Sessions in New Orleans on Sunday, June 7, showing that nearly 1 in 5 patients ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...

In SYNCHRONIZE-1, survodutide achieved −12.2% to −13.0% weight loss at 76 weeks versus −5.4% with placebo, with ≥20% loss in 28.5% at 6.0 mg. MRI substudy data showed organ-selective effects: liver ...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

NEW ORLEANS — Survodutide, an investigational glucagon receptor/GLP-1 receptor dual agonist, produced significant weight loss along with reductions in visceral fat and liver fat in two phase 3 trials.

The 76-week Phase III SYNCHRONIZE-1 trial investigated survodutide in adults living with obesity or overweight, without type 2 diabetes. Positive topline data announced in April showed that the trial ...